Agios Pharmaceuticals is implementing significant workforce reductions within its research and development division. The company aims to eliminate over 100 R&D roles by the end of the year. These cuts are intended to decrease the R&D headcount by more than 35% compared to 2025 levels. The anticipated cost savings from these reductions are projected to be realized in 2027. This strategic move comes as Agios awaits a potential FDA approval for its anemia medicine in sickle cell disease.
Cambridge, Massachusetts
https://www.fiercebiotech.com/biotech/agios-aims-shed-100-rd-roles-year-ahead-hoped-scd-approval